Use of betahistine medications for vertigo

Abstract

A post-registration, open randomized comparative trial of clinical efficacy and safety of betahistine medications Vestikap and Betaserc in patients with vestibular vertigo was carried out. 62 patients met the inclusion criteria and were included in the observation: 17 men and 45 women, mean age 47 ± 13,1 years. The treatment regimen was completed by all 62 patients. Administration of either medication was associated with a significant clinical benefit reflected in vertigo reduction by the vertigo severity scale and improved quality of life by the Dizziness Handicap Inventory. No significant differences were revealed in the efficacy, tolerability or safety of treatment with Vestikap compared with Betaserc